Filing Details
- Accession Number:
- 0001415889-24-029964
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-12-20 16:06:42
- Reporting Period:
- 2024-12-18
- Accepted Time:
- 2024-12-20 16:06:42
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1831828 | Vera Therapeutics Inc. | VERA | Pharmaceutical Preparations (2834) | 812744449 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1859453 | Marshall Fordyce | C/O Vera Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 1200 Brisbane CA 94005 | President And Ceo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Acquisiton | 2024-12-18 | 3,772 | $2.90 | 89,714 | No | 4 | M | Direct | |
| Class A Common Stock | Disposition | 2024-12-18 | 3,772 | $41.33 | 85,942 | No | 4 | S | Direct | |
| Class A Common Stock | Acquisiton | 2024-12-18 | 2,195 | $2.90 | 88,137 | No | 4 | M | Direct | |
| Class A Common Stock | Disposition | 2024-12-18 | 2,195 | $42.35 | 85,942 | No | 4 | S | Direct | |
| Class A Common Stock | Acquisiton | 2024-12-18 | 5,023 | $2.90 | 90,965 | No | 4 | M | Direct | |
| Class A Common Stock | Disposition | 2024-12-18 | 5,023 | $43.52 | 85,942 | No | 4 | S | Direct | |
| Class A Common Stock | Acquisiton | 2024-12-18 | 4,635 | $2.90 | 90,577 | No | 4 | M | Direct | |
| Class A Common Stock | Disposition | 2024-12-18 | 4,635 | $44.03 | 85,942 | No | 4 | S | Direct | |
| Class A Common Stock | Acquisiton | 2024-12-18 | 1,875 | $2.90 | 87,817 | No | 4 | M | Direct | |
| Class A Common Stock | Disposition | 2024-12-18 | 1,875 | $43.81 | 85,942 | No | 4 | S | Direct | |
| Class A Common Stock | Acquisiton | 2024-12-19 | 57,661 | $2.90 | 143,603 | No | 4 | M | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Class A Common Stock | Stock Option (Right to Buy) | Disposition | 2024-12-18 | 15,625 | $0.00 | 15,625 | $2.90 |
| Class A Common Stock | Stock Option (Right to Buy) | Disposition | 2024-12-18 | 1,875 | $0.00 | 1,875 | $2.90 |
| Class A Common Stock | Stock Option (Right to Buy) | Disposition | 2024-12-19 | 57,661 | $0.00 | 57,661 | $2.90 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 686,087 | 2030-12-15 | No | 4 | M | Direct | |
| 684,212 | 2030-12-15 | No | 4 | M | Direct | |
| 626,551 | 2030-12-15 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Class A Common Stock | 222,030 | Indirect | By GRAT |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024.
- The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.87 to $41.82, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.88 to $42.74, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.88 to $43.87, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.88 to $44.32, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter.
Billionaire Hedge Funds
